Susquehanna International Group’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $215K | Buy |
+127,300
| New | +$226K | ﹤0.01% | 11544 |
|
|
2024
Q4 | – | Sell |
-10,600
| Closed | -$11K | – | 12281 |
|
|
2024
Q3 | $11K | Sell |
10,600
-38,500
| -78% | -$52.8K | ﹤0.01% | 11712 |
|
|
2024
Q2 | $84.9K | Sell |
49,100
-24,100
| -33% | -$48.5K | ﹤0.01% | 11126 |
|
|
2024
Q1 | $175K | Sell |
73,200
-68,500
| -48% | -$169K | ﹤0.01% | 10745 |
|
|
2023
Q4 | $472K | Sell |
141,700
-71,200
| -33% | -$191K | ﹤0.01% | 8811 |
|
|
2023
Q3 | $796K | Buy |
212,900
+135,700
| +176% | +$627K | ﹤0.01% | 7154 |
|
|
2023
Q2 | $330K | Buy |
+77,200
| New | +$456K | ﹤0.01% | 9250 |
|
|
2023
Q1 | – | Sell |
-43,000
| Closed | -$341K | – | 12639 |
|
|
2022
Q4 | $341K | Buy |
+43,000
| New | +$331K | ﹤0.01% | 8794 |
|
|
2021
Q4 | – | Sell |
-19,000
| Closed | -$305K | – | 13164 |
|
|
2021
Q3 | $305K | Buy |
19,000
+4,800
| +34% | +$70.4K | ﹤0.01% | 10566 |
|
|
2021
Q2 | $196K | Sell |
14,200
-13,200
| -48% | -$187K | ﹤0.01% | 11621 |
|
|
2021
Q1 | $400K | Sell |
27,400
-4,500
| -14% | -$76.4K | ﹤0.01% | 9985 |
|
|
2020
Q4 | $554K | Sell |
31,900
-15,100
| -32% | -$269K | ﹤0.01% | 8057 |
|
|
2020
Q3 | $862K | Buy |
47,000
+4,600
| +11% | +$85.6K | ﹤0.01% | 6482 |
|
|
2020
Q2 | $757K | Sell |
42,400
-33,000
| -44% | -$559K | ﹤0.01% | 6499 |
|
|
2020
Q1 | $1.22M | Sell |
75,400
-3,700
| -5% | -$68.4K | ﹤0.01% | 4921 |
|
|
2019
Q4 | $1.42M | Sell |
79,100
-21,500
| -21% | -$397K | ﹤0.01% | 4888 |
|
|
2019
Q3 | $2.04M | Buy |
100,600
+78,600
| +357% | +$1.57M | ﹤0.01% | 4146 |
|
|
2019
Q2 | $486K | Buy |
22,000
+4,700
| +27% | +$81.6K | ﹤0.01% | 7322 |
|
|
2019
Q1 | $236K | Sell |
17,300
-44,000
| -72% | -$587K | ﹤0.01% | 7617 |
|
|
2018
Q4 | $555K | Buy |
61,300
+24,600
| +67% | +$285K | ﹤0.01% | 5817 |
|
|
2018
Q3 | $606K | Sell |
36,700
-71,500
| -66% | -$1.27M | ﹤0.01% | 6174 |
|
|
2018
Q2 | $1.51M | Buy |
108,200
+70,700
| +189% | +$1.01M | ﹤0.01% | 4523 |
|
|
2018
Q1 | $414K | Buy |
37,500
+15,900
| +74% | +$174K | ﹤0.01% | 7014 |
|
|
2017
Q4 | $190K | Sell |
21,600
-41,900
| -66% | -$449K | ﹤0.01% | 8318 |
|
|
2017
Q3 | $848K | Sell |
63,500
-1,000
| -2% | -$13.2K | ﹤0.01% | 5570 |
|
|
2017
Q2 | $926K | Buy |
64,500
+22,400
| +53% | +$431K | ﹤0.01% | 5416 |
|
|
2017
Q1 | $890K | Buy |
42,100
+29,600
| +237% | +$728K | ﹤0.01% | 5366 |
|
|
2016
Q4 | $352K | Sell |
12,500
-4,300
| -26% | -$120K | ﹤0.01% | 7664 |
|
|
2016
Q3 | $450K | Buy |
+16,800
| New | +$458K | ﹤0.01% | 6266 |
|
|
2015
Q4 | – | Sell |
-23,500
| Closed | -$471K | – | 9451 |
|
|
2015
Q3 | $471K | Buy |
+23,500
| New | +$715K | ﹤0.01% | 7241 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Susquehanna International Group's CHRS Position: Q1 2026 in Review
Susquehanna International Group reduced its Coherus Oncology (CHRS) stake by 25% in Q1 2026, selling an estimated $168K and leaving 287,500 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #9750.
Susquehanna International Group first reported a position in CHRS in Q4 2014 and has held it in 33 quarters since. The position peaked at $2.83M in Q2 2023. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Susquehanna International Group held 287,500 shares of Coherus Oncology worth $486K as of Q1 2026.
- Susquehanna International Group sold 94,741 Coherus Oncology shares in Q1 2026, an estimated $168K.
- Coherus Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9750 holding.
- Susquehanna International Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 33 quarters since.
- Susquehanna International Group's Coherus Oncology position peaked at $2.83M in Q2 2023.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.